{
  "name": "Synptide Compound Regulatory-Status & Evidence Map",
  "version": "1.0",
  "updated": "2026-07-11",
  "license": "CC BY 4.0",
  "citation": "Synptide Compound Evidence Map, v1.0 (synptide.com/datasets)",
  "methodology": "https://synptide.com/methodology",
  "count": 25,
  "compounds": [
    {
      "slug": "bpc-157",
      "name": "BPC-157",
      "aliases": "Body Protection Compound 157; PL 14736; Bepecin",
      "brandNames": "",
      "compoundClass": "Synthetic pentadecapeptide",
      "category": "peptides",
      "approvalStatus": "Research chemical",
      "halfLife": "Not well characterized in humans.",
      "wadaStatus": "Prohibited — BPC-157 falls under WADA's S0 (non-approved substances) category.",
      "evidenceByOutcome": "Tendon and ligament healing: D (Preclinical); Gut / GI protection: D (Preclinical); Muscle and soft-tissue recovery: D (Preclinical); Any long-term safety outcome: U (Unknown)",
      "url": "https://synptide.com/compounds/bpc-157"
    },
    {
      "slug": "cagrilintide",
      "name": "Cagrilintide",
      "aliases": "AM833; NNC0174-0833",
      "brandNames": "",
      "compoundClass": "Long-acting amylin (and calcitonin) receptor agonist",
      "category": "glp-1",
      "approvalStatus": "Investigational",
      "halfLife": "~8 days (supports once-weekly dosing)",
      "wadaStatus": "Not prohibited by WADA.",
      "evidenceByOutcome": "Weight loss (as monotherapy): B (Supported); Weight loss (combined with semaglutide, \"CagriSema\"): B (Supported); Glycemic control (type 2 diabetes): C (Preliminary); Cardiovascular risk reduction: U (Unknown); Lean-mass preservation: D (Preclinical)",
      "url": "https://synptide.com/compounds/cagrilintide"
    },
    {
      "slug": "cjc-1295",
      "name": "CJC-1295",
      "aliases": "CJC-1295 DAC; CJC-1295 with DAC; Modified GRF (1-29); Mod GRF 1-29; DAC:GRF",
      "brandNames": "",
      "compoundClass": "Long-acting GHRH analog",
      "category": "peptides",
      "approvalStatus": "Research chemical",
      "halfLife": "With DAC, roughly 6–8 days (albumin binding). Without DAC (Modified GRF 1-29), about 30 minutes.",
      "wadaStatus": "Prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances and mimetics), which covers GHRH and its analogs.",
      "evidenceByOutcome": "Raises GH and IGF-1 secretion: C (Preliminary); Fat loss / body-composition change: U (Unknown); Muscle growth / lean mass: U (Unknown); Anti-aging / recovery / sleep: E (Unsupported); Long-term safety: U (Unknown)",
      "url": "https://synptide.com/compounds/cjc-1295"
    },
    {
      "slug": "dulaglutide",
      "name": "Dulaglutide",
      "aliases": "",
      "brandNames": "Trulicity",
      "compoundClass": "GLP-1 receptor agonist",
      "category": "glp-1",
      "approvalStatus": "FDA-approved",
      "halfLife": "~5 days (supports once-weekly dosing)",
      "wadaStatus": "Not prohibited by WADA.",
      "evidenceByOutcome": "Glycemic control (type 2 diabetes): A (Established); Cardiovascular risk reduction: A (Established); Weight loss: B (Supported); Lean-mass preservation: D (Preclinical)",
      "url": "https://synptide.com/compounds/dulaglutide"
    },
    {
      "slug": "epitalon",
      "name": "Epitalon",
      "aliases": "Epithalon; Epithalone; AEDG peptide; Ala-Glu-Asp-Gly",
      "brandNames": "",
      "compoundClass": "Synthetic tetrapeptide",
      "category": "longevity",
      "approvalStatus": "Research chemical",
      "halfLife": "Not well characterized; the native peptide is thought to be very short-lived in circulation.",
      "wadaStatus": "Not individually named on the WADA Prohibited List; as a non-approved peptide it may fall under the S0 (non-approved substances) category. Athletes should treat it as prohibited.",
      "evidenceByOutcome": "Telomerase activation / telomere elongation: D (Preclinical); Lifespan / tumor incidence (animals): D (Preclinical); Human aging biomarkers (melatonin rhythm, mortality in older cohorts): C (Preliminary); Long-term human safety: U (Unknown)",
      "url": "https://synptide.com/compounds/epitalon"
    },
    {
      "slug": "exenatide",
      "name": "Exenatide",
      "aliases": "Exendin-4",
      "brandNames": "Byetta; Bydureon",
      "compoundClass": "GLP-1 receptor agonist",
      "category": "glp-1",
      "approvalStatus": "FDA-approved",
      "halfLife": "~2.4 hours (immediate-release Byetta); extended-release Bydureon is dosed weekly via microsphere delivery",
      "wadaStatus": "Not prohibited by WADA.",
      "evidenceByOutcome": "Glycemic control (type 2 diabetes): A (Established); Cardiovascular risk reduction: E (Unsupported); Weight loss: C (Preliminary); Lean-mass preservation: D (Preclinical)",
      "url": "https://synptide.com/compounds/exenatide"
    },
    {
      "slug": "ghk-cu",
      "name": "GHK-Cu",
      "aliases": "Copper tripeptide-1; Copper peptide; Glycyl-L-histidyl-L-lysine copper; GHK copper complex",
      "brandNames": "",
      "compoundClass": "Copper-binding tripeptide (glycyl-L-histidyl-L-lysine + Cu2+)",
      "category": "longevity",
      "approvalStatus": "Status varies by jurisdiction",
      "halfLife": "Not well characterized; endogenous plasma GHK declines with age.",
      "wadaStatus": "",
      "evidenceByOutcome": "Skin appearance — wrinkles, firmness, texture (topical): C (Preliminary); Wound healing (topical/experimental): D (Preclinical); Hair growth: D (Preclinical); Systemic anti-aging / regenerative effects (injected): U (Unknown); Any long-term safety outcome for injected use: U (Unknown)",
      "url": "https://synptide.com/compounds/ghk-cu"
    },
    {
      "slug": "ghrp-2",
      "name": "GHRP-2",
      "aliases": "Growth Hormone-Releasing Peptide-2; Pralmorelin; KP-102; GPA-748",
      "brandNames": "",
      "compoundClass": "Synthetic growth-hormone-releasing peptide (ghrelin receptor agonist)",
      "category": "peptides",
      "approvalStatus": "Research chemical",
      "halfLife": "Short — roughly 30-40 minutes in human pharmacokinetic studies.",
      "wadaStatus": "Prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances, and mimetics), alongside other GH-releasing peptides.",
      "evidenceByOutcome": "Acute increase in growth hormone secretion: C (Preliminary); Increased appetite / food intake: C (Preliminary); Muscle growth / body-composition benefit: E (Unsupported); Anti-aging / longevity benefit: E (Unsupported); Any long-term safety outcome: U (Unknown)",
      "url": "https://synptide.com/compounds/ghrp-2"
    },
    {
      "slug": "ghrp-6",
      "name": "GHRP-6",
      "aliases": "Growth Hormone-Releasing Peptide-6; Hexapeptide-2; SKF-110679; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2",
      "brandNames": "",
      "compoundClass": "Synthetic growth-hormone-releasing hexapeptide (ghrelin receptor agonist)",
      "category": "peptides",
      "approvalStatus": "Research chemical",
      "halfLife": "Short — on the order of tens of minutes in humans; not precisely characterized.",
      "wadaStatus": "Prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances, and mimetics).",
      "evidenceByOutcome": "Acute increase in growth hormone secretion: C (Preliminary); Increased appetite / food intake: C (Preliminary); Muscle growth / body-composition benefit: E (Unsupported); Tissue repair / recovery benefit: E (Unsupported); Any long-term safety outcome: U (Unknown)",
      "url": "https://synptide.com/compounds/ghrp-6"
    },
    {
      "slug": "ipamorelin",
      "name": "Ipamorelin",
      "aliases": "NNC 26-0161",
      "brandNames": "",
      "compoundClass": "Selective ghrelin/GH-secretagogue receptor agonist",
      "category": "peptides",
      "approvalStatus": "Research chemical",
      "halfLife": "Roughly 2 hours in humans.",
      "wadaStatus": "Prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances and mimetics), which covers GH-releasing peptides and secretagogues.",
      "evidenceByOutcome": "Raises GH secretion: C (Preliminary); Postoperative ileus (recovery of bowel function): E (Unsupported); Fat loss / body-composition change: U (Unknown); Muscle growth / recovery / anti-aging: U (Unknown); Long-term safety: U (Unknown)",
      "url": "https://synptide.com/compounds/ipamorelin"
    },
    {
      "slug": "kpv",
      "name": "KPV",
      "aliases": "Lysine-Proline-Valine; Lys-Pro-Val; alpha-MSH(11-13); α-MSH C-terminal tripeptide",
      "brandNames": "",
      "compoundClass": "Anti-inflammatory tripeptide (C-terminal fragment of alpha-MSH)",
      "category": "peptides",
      "approvalStatus": "Research chemical",
      "halfLife": "Not characterized in humans.",
      "wadaStatus": "",
      "evidenceByOutcome": "Intestinal / colonic inflammation (colitis): D (Preclinical); General anti-inflammatory / immune modulation: D (Preclinical); Skin inflammation / wound healing: D (Preclinical); Any long-term safety outcome: U (Unknown)",
      "url": "https://synptide.com/compounds/kpv"
    },
    {
      "slug": "liraglutide",
      "name": "Liraglutide",
      "aliases": "",
      "brandNames": "Victoza; Saxenda",
      "compoundClass": "GLP-1 receptor agonist",
      "category": "glp-1",
      "approvalStatus": "FDA-approved",
      "halfLife": "~13 hours (supports once-daily dosing)",
      "wadaStatus": "Not prohibited by WADA.",
      "evidenceByOutcome": "Glycemic control (type 2 diabetes): A (Established); Cardiovascular risk reduction: A (Established); Weight loss: A (Established); Lean-mass preservation: D (Preclinical)",
      "url": "https://synptide.com/compounds/liraglutide"
    },
    {
      "slug": "ll-37",
      "name": "LL-37",
      "aliases": "Cathelicidin antimicrobial peptide; hCAP-18 fragment; CAMP; Cathelicidin LL-37",
      "brandNames": "",
      "compoundClass": "Human cathelicidin-derived antimicrobial / host-defense peptide (37 residues)",
      "category": "peptides",
      "approvalStatus": "Research chemical",
      "halfLife": "Not well characterized; rapidly regulated in tissue.",
      "wadaStatus": "",
      "evidenceByOutcome": "Antimicrobial / innate immune defense (endogenous role): D (Preclinical); Wound healing: D (Preclinical); Anti-cancer activity: D (Preclinical); Any therapeutic use in humans: U (Unknown); Any long-term safety outcome: U (Unknown)",
      "url": "https://synptide.com/compounds/ll-37"
    },
    {
      "slug": "mk-677",
      "name": "MK-677",
      "aliases": "Ibutamoren; Ibutamoren mesylate; MK-0677; L-163191",
      "brandNames": "",
      "compoundClass": "Orally-active non-peptide ghrelin receptor agonist / growth hormone secretagogue",
      "category": "peptides",
      "approvalStatus": "Investigational",
      "halfLife": "Roughly 4-6 hours in humans; supports once-daily oral dosing with sustained IGF-1 elevation.",
      "wadaStatus": "Prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances, and mimetics). Ibutamoren is explicitly named on the prohibited list.",
      "evidenceByOutcome": "Sustained increase in growth hormone and IGF-1: B (Supported); Increase in fat-free (lean) mass: C (Preliminary); Improved strength or physical function: E (Unsupported); Slowing Alzheimer's disease progression: E (Unsupported); Anti-aging / longevity benefit: E (Unsupported); Any long-term safety outcome: U (Unknown)",
      "url": "https://synptide.com/compounds/mk-677"
    },
    {
      "slug": "mots-c",
      "name": "MOTS-c",
      "aliases": "Mitochondrial ORF of the 12S rRNA type-c; MOTSc; MOTS-C",
      "brandNames": "",
      "compoundClass": "Mitochondrial-derived peptide",
      "category": "longevity",
      "approvalStatus": "Research chemical",
      "halfLife": "Not well characterized in humans.",
      "wadaStatus": "Not individually named on the WADA Prohibited List, but as a non-approved peptide it is likely captured by the S0 (non-approved substances) category; athletes should treat it as prohibited.",
      "evidenceByOutcome": "Metabolic health / insulin sensitivity: D (Preclinical); Exercise capacity / mitochondrial function: D (Preclinical); Longevity / healthspan: U (Unknown); Long-term human safety: U (Unknown)",
      "url": "https://synptide.com/compounds/mots-c"
    },
    {
      "slug": "orforglipron",
      "name": "Orforglipron",
      "aliases": "LY3502970; OWL833",
      "brandNames": "",
      "compoundClass": "Oral non-peptide (small-molecule) GLP-1 receptor agonist",
      "category": "glp-1",
      "approvalStatus": "Investigational",
      "halfLife": "~29–49 hours (supports once-daily dosing)",
      "wadaStatus": "Not prohibited by WADA.",
      "evidenceByOutcome": "Weight loss: B (Supported); Glycemic control (type 2 diabetes): B (Supported); Cardiovascular risk reduction: C (Preliminary); Lean-mass preservation: D (Preclinical)",
      "url": "https://synptide.com/compounds/orforglipron"
    },
    {
      "slug": "retatrutide",
      "name": "Retatrutide",
      "aliases": "LY3437943",
      "brandNames": "",
      "compoundClass": "Triple GIP / GLP-1 / glucagon receptor agonist",
      "category": "glp-1",
      "approvalStatus": "Investigational",
      "halfLife": "~6 days (supports once-weekly dosing)",
      "wadaStatus": "Not specifically listed by WADA.",
      "evidenceByOutcome": "Weight loss: C (Preliminary); Glycemic control (type 2 diabetes): C (Preliminary); Cardiovascular risk reduction: U (Unknown); Lean-mass preservation: D (Preclinical)",
      "url": "https://synptide.com/compounds/retatrutide"
    },
    {
      "slug": "selank",
      "name": "Selank",
      "aliases": "Selanc; TP-7; Tuftsin analog; Thr-Lys-Pro-Arg-Pro-Gly-Pro",
      "brandNames": "Selank",
      "compoundClass": "Synthetic heptapeptide (Tuftsin analog)",
      "category": "longevity",
      "approvalStatus": "Status varies by jurisdiction",
      "halfLife": "Short in plasma; the Pro-Gly-Pro extension of tuftsin improves metabolic stability. Not well characterized by Western standards.",
      "wadaStatus": "Not individually named on the WADA Prohibited List. Its international regulatory status is ambiguous; athletes should verify before use.",
      "evidenceByOutcome": "Anxiety (generalized anxiety, adjustment/neurasthenia): C (Preliminary); Cognitive / attention effects: D (Preclinical); GABAergic / neurochemical mechanism: D (Preclinical); Long-term human safety: U (Unknown)",
      "url": "https://synptide.com/compounds/selank"
    },
    {
      "slug": "semaglutide",
      "name": "Semaglutide",
      "aliases": "",
      "brandNames": "Ozempic; Wegovy; Rybelsus",
      "compoundClass": "GLP-1 receptor agonist",
      "category": "glp-1",
      "approvalStatus": "FDA-approved",
      "halfLife": "~7 days (supports once-weekly dosing)",
      "wadaStatus": "Not prohibited by WADA.",
      "evidenceByOutcome": "Glycemic control (type 2 diabetes): A (Established); Weight loss: A (Established); Cardiovascular risk reduction: A (Established); Lean-mass preservation: D (Preclinical)",
      "url": "https://synptide.com/compounds/semaglutide"
    },
    {
      "slug": "semax",
      "name": "Semax",
      "aliases": "Semaks; ACTH(4-7) analog; Met-Glu-His-Phe-Pro-Gly-Pro",
      "brandNames": "Semax",
      "compoundClass": "Synthetic heptapeptide (ACTH(4-7) analog)",
      "category": "longevity",
      "approvalStatus": "Status varies by jurisdiction",
      "halfLife": "Short in plasma; a modified sequence gives a longer central duration of action than native ACTH fragments. Not well characterized by Western standards.",
      "wadaStatus": "Not individually named on the WADA Prohibited List. Because it is approved in Russia its regulatory status is ambiguous internationally; athletes should verify before use.",
      "evidenceByOutcome": "Cognitive / nootropic effects: C (Preliminary); Ischemic stroke / neuroprotection recovery: C (Preliminary); BDNF / neurotrophic mechanism: D (Preclinical); Long-term human safety: U (Unknown)",
      "url": "https://synptide.com/compounds/semax"
    },
    {
      "slug": "sermorelin",
      "name": "Sermorelin",
      "aliases": "Sermorelin acetate; GRF (1-29); GHRH (1-29)",
      "brandNames": "Geref",
      "compoundClass": "GHRH (1-29) analog",
      "category": "peptides",
      "approvalStatus": "Withdrawn",
      "halfLife": "Very short — roughly 10–20 minutes.",
      "wadaStatus": "Prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances and mimetics), which covers GHRH and its analogs.",
      "evidenceByOutcome": "Stimulates GH release (diagnostic / pediatric GH deficiency): B (Supported); Adult anti-aging / body composition / sleep / vitality: U (Unknown); Long-term safety in off-label adult use: U (Unknown)",
      "url": "https://synptide.com/compounds/sermorelin"
    },
    {
      "slug": "tb-500",
      "name": "TB-500",
      "aliases": "TB500; Thymosin Beta-4 Fragment; Tβ4 fragment; TB4 fragment",
      "brandNames": "",
      "compoundClass": "Synthetic peptide fragment (related to Thymosin beta-4)",
      "category": "recovery",
      "approvalStatus": "Research chemical",
      "halfLife": "Not well characterized in humans.",
      "wadaStatus": "Prohibited at all times in sport. TB-500 and Thymosin beta-4 fall under WADA's S2 category (peptide hormones, growth factors, related substances, and mimetics).",
      "evidenceByOutcome": "Tendon and ligament healing: D (Preclinical); Muscle and soft-tissue recovery: D (Preclinical); Wound healing: D (Preclinical); Cardiac / tissue regeneration: D (Preclinical); Any long-term safety outcome: U (Unknown)",
      "url": "https://synptide.com/compounds/tb-500"
    },
    {
      "slug": "tesamorelin",
      "name": "Tesamorelin",
      "aliases": "TH9507",
      "brandNames": "Egrifta; Egrifta SV; Egrifta WR",
      "compoundClass": "Stabilized GHRH analog",
      "category": "peptides",
      "approvalStatus": "FDA-approved",
      "halfLife": "Short — roughly 26–38 minutes.",
      "wadaStatus": "Prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances and mimetics), which covers GHRH and its analogs.",
      "evidenceByOutcome": "Visceral adipose tissue reduction (HIV lipodystrophy): A (Established); Triglyceride / lipid improvement (HIV lipodystrophy): B (Supported); Liver fat / NAFLD reduction: C (Preliminary); Fat loss / body composition in non-HIV or general anti-aging use: U (Unknown)",
      "url": "https://synptide.com/compounds/tesamorelin"
    },
    {
      "slug": "thymosin-beta-4",
      "name": "Thymosin Beta-4",
      "aliases": "Thymosin β4; Tβ4; TB4; RGN-259 (ophthalmic formulation)",
      "brandNames": "",
      "compoundClass": "Naturally occurring 43-amino-acid actin-binding peptide",
      "category": "recovery",
      "approvalStatus": "Investigational",
      "halfLife": "Short in circulation; not fully characterized across formulations in humans.",
      "wadaStatus": "Prohibited at all times in sport under WADA's S2 category (peptide hormones, growth factors, related substances, and mimetics).",
      "evidenceByOutcome": "Corneal / ophthalmic wound healing (neurotrophic keratopathy, dry eye): C (Preliminary); Dermal / cutaneous wound healing: C (Preliminary); Cardiac repair after injury: D (Preclinical); Musculoskeletal / tendon and muscle recovery: D (Preclinical); Any long-term systemic safety outcome: U (Unknown)",
      "url": "https://synptide.com/compounds/thymosin-beta-4"
    },
    {
      "slug": "tirzepatide",
      "name": "Tirzepatide",
      "aliases": "",
      "brandNames": "Mounjaro; Zepbound",
      "compoundClass": "Dual GIP / GLP-1 receptor agonist",
      "category": "glp-1",
      "approvalStatus": "FDA-approved",
      "halfLife": "~5 days (supports once-weekly dosing)",
      "wadaStatus": "Not prohibited by WADA.",
      "evidenceByOutcome": "Weight loss: A (Established); Glycemic control (type 2 diabetes): A (Established); Obstructive sleep apnea: A (Established); Cardiovascular risk reduction: C (Preliminary); Lean-mass preservation: D (Preclinical)",
      "url": "https://synptide.com/compounds/tirzepatide"
    }
  ]
}